LUNG Financials

Income Statement
MetricQ2 2026Q1 2026Q4 2025Q3 2025Q2 2025
Revenue
22.8M
+10.5%
20.6M
-8.9%
22.6M
+5.1%
21.5M
-9.9%
23.9M
Cost of Revenue
5.0M
+10.4%
4.5M
-10.2%
5.1M
-7.2%
5.5M
-18.1%
6.7M
Gross Profit
17.7M
+10.6%
16.0M
-8.5%
17.5M
+9.3%
16.1M
-6.7%
17.2M
Operating Expenses
26.8M
-7.6%
29.0M
+5.7%
27.4M
-9.9%
30.4M
-4.9%
32.0M
R&D
5.0M
+2.8%
4.9M
+6.9%
4.6M
-5.4%
4.8M
-8.7%
5.3M
SG&A
21.8M
-9.7%
24.1M
+5.4%
22.9M
-10.7%
25.6M
-4.1%
26.7M
Operating Income
-9057000
+30.1%
-12956000
-30.8%
-9903000
+31.2%
-14393000
+2.8%
-14804000
EBITDA
-8835000
+30.6%
-12736000
-31.7%
-9672000
+31.6%
-14147000
+2.5%
-14505000
Net Income
-10080000
+26.2%
-13654000
-31.0%
-10425000
+25.3%
-13957000
+8.0%
-15173000
EPS (Basic)
$-0.24
+27.3%
$-0.33
-32.0%
$-0.25
+26.5%
$-0.34
+10.5%
$-0.38
EPS (Diluted)
$-0.24
+27.3%
$-0.33
-32.0%
$-0.25
+26.5%
$-0.34
+10.5%
$-0.38
Shares (Diluted)
42.5M
+1.4%
41.9M
+1.1%
41.4M
+1.2%
40.9M
+1.3%
40.4M
Pulmonx (LUNG) โ€” Financials